Metabolomics of Ramadan fasting and associated risk of chronic diseases

Background: The dramatic change in lifestyle associated with Ramadan fasting raises questions about its effect on metabolism and health. Metabolites, as the end product of metabolism, are excellent candidates to be studied in this regard. Objective: This study aims to investigate the effect of Ramadan fasting on the metabolic pro fi le and risk of chronic diseases. Methods: The London Ramadan study (LORANS) is an observational study in which 2 blood samples were collected from 72 participants a few days before and after the fasting month of Ramadan. We conducted metabolomic pro fi ling using nuclear magnetic resonance spectroscopy to assess the change in individual metabolites from before to after Ramadan. Also, we generated metabolic scores (scaled from 0 to 100) for 7 chronic diseases in the UK Biobank and assessed the association of Ramadan fasting with these scores in LORANS. Results: Of the 72 participants, 35 were male (48.6%); the mean ( +/- standard deviation) age was 45.7 ( +/- 16) y. Ramadan fasting was associated with changes in 14 metabolites (1 in fl ammation marker, 1 amino acid, 2 glycolysis-related metabolites, 2 ketone bodies, 2 triglyceride, and 6 lipoprotein subclasses), independent of changes in body composition. Using data from 117,981 participants in the UK Biobank, we generated metabolic scores for diabetes, hypertension, coronary artery disease, renal failure, colorectal cancer, breast cancer, and lung cancer. The metabolic scores for lung cancer, colorectal cancer, and breast cancer were lower after Ramadan in LORANS ( - 4.74, 9.6%, 95% con fi dence interval - 6.56, - 2.91, P < 0.001), ( - 1.09, - 2.4%, - 1.69, - 0. 50, P < 0.001), and ( - 0.48, - 1.1%, - 0. 81, - 0.15, P = 0.006), respectively. Conclusions: Ramadan fasting is associated with short -term favorable changes in the metabolic pro fi le concerning risk of some chronic diseases. These findings should be further investigated in future, larger studies of longer follow-up with clinical outcomes.